Asia-Pacific HAE Therapeutics Markets to 2023 - Growth Driven by Ongoing Shift towards Plasma-Derivative Products and Expected Launch of Premium Therapies - ResearchAndMarkets.com

DUBLIN--()--The "HAE Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Ongoing Shift towards Plasma-Derivative Products and Expected Launch of Premium Therapies" report has been added to ResearchAndMarkets.com's offering.

Most significantly, the HAE market lacks curative treatments, as current therapies aim to alleviate symptoms and reduce disease progression. This major unmet need is not expected to be addressed directly by any of the pipeline agents. Additionally, any pipeline candidates that will be successfully approved and launched will compete for the same patient populations although late-stage drugs are likely to address the need for a more convenient route of administration, as the pipeline contains potential kallikrein inhibitors that can be administered orally. Products with novel mechanisms of action and safer and more efficacious profiles will be welcome additions to the market.

Scope of the Report

  • The current Asia-Pacific HAE market contains premium therapies such as Berinert, Cinryze, Ruconest and Firazyr.
  • What are the competitive advantages of the existing premium therapies?
  • There are 24 active pipeline molecules, and the late-stage investigational drug candidates feature improved administration routes compared with currently marketed products.
  • Which classes of re-formulation drugs are most prominent in the pipeline?
  • What is the potential for pipeline products to address unmet needs in the HAE market?
  • Analysis of clinical trials since 2006 identified that the failure rates of HAE molecules were highest in Phase III, at 14.3%.
  • How do failure rates vary by stage of development, molecule type, and molecular target?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
  • Over the 2016-2023 forecast period, the Asia-Pacific HAE therapeutics market is expected to grow at a CAGR of 9.6%, from $54.5m to over $103.5m.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes to annual therapy costs?
  • How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?
  • The rising HAE prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period.
  • Will the launch of emerging pipeline molecules threaten the commercial success of existing drugs?
  • Licensing deals are the most common form of strategic alliance in the HAE therapeutics market, with deal values ranging from $2.7m to over $83m.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Marketed Products

4 Pipeline Analysis

5 Clinical Trial Analysis

6 Multi-scenario Forecast

7 Market Dynamics (Drivers and Barriers) of HAE Market

8 Deals and Strategic Consolidations

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/gdwfss/asiapacific_hae?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs